ASHM supports the health workforce in Hepatitis C across Australia and New Zealand.


 

 

The advent of curative DAA treatment is the most significant advance in clinical management of HCV in decades and has brought with it an unprecedented opportunity to change the course of the epidemic.  

  • In 2016, the Australian Government made a major investment in DAA treatment and initiated changes to prescribing rules to support the broadest possible access to these medicines, crucially, this includes increasing access to treatment in primary care. 

  • DAA treatments provide a cure for well over 90 per cent of people treated, are well tolerated and have a short treatment duration (8 to 24 weeks). 

  • All people living with HCV should be considered for treatment. 

Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2017 

Prepared by an expert panel, this document provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment. It is available in various formats: 

View the website at www.hepcguidelines.org.au 

Under the Pharmaceutical Benefits Scheme (PBS) General Schedule, prescriptions for HCV treatment may be written by a medical practitioner or an authorised nurse practitioner experienced in the treatment of chronic HCV infection; or in consultation with a gastroenterologist, hepatologist or infectious diseases physician experienced in the treatment of chronic HCV infection.  

General Statement for Drugs for the Treatment of Hepatitis C

Training 

ASHM supports medical practitioners in primary care to increase their knowledge and experience enabling them to prescribe treatment for HCV. To find training near you see our Training Locator Map or for further information or support contact education@ashm.org.au 

Real world efficacy of antiviral therapy in chronic hepatitis C (REACH-C) in Australia 

ASHM, in collaboration with the Kirby Institute, has developed an online form for medical practitioners to complete to gain specialist approval to initiate DAA therapy. Specialists highly experienced in HCV treatment will review the form and either approve the treatment choice or request that further information be provided. The anticipated turn-around time for specialist approval sought via the REACH-C online form is 24 hours.   

This work is part of a national prospective multi-centre observational cohort study titled REACH-C which aims to evaluate uptake and real-world outcomes of direct acting anti-viral therapy for HCV in Australia. To find out more, see the REACH-Cwebsite or download the latest REACH-C Newsletter

Developed by GESA-Australian Liver Association, this template can be used by medical practitioners, including general practitioners, to consult with a gastroenterologist, hepatologist, or infectious disease physician experienced in the treatment of chronic hepatitis C infection, in order to prescribe new treatments under the PBS.

Prepared by an expert panel, this document provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment. It is available in various formats: 

View the website at www.hepcguidelines.org.au 

For details on hepatitis C treatment uptake in Australia since the PBS listing of new direct acting antivirals (DAAs) from 1 March 2016, access The Kirby Institute's (University of New South Wales) Viral Hepatitis Clinical Research Program newsletters titled Monitoring hepatitis C treatment uptake in Australia